CORDIS
Risultati della ricerca dell’UE

CORDIS

Italiano IT

European IPF Network: Natural course, Pathomechanisms and Novel Treatment Options in Idiopathic Pulmonary Fibrosis

Obiettivo

In the eurIPFnet consortium, leading European basic and clinical scientists in the field of interstitial lung diseases associate to jointly decipher the natural course and molecular pathomechanisms of Idiopathic Pulmonary Fibrosis (IPF) and to develop new therapeutic strategies for patients with IPF. This devastating disease affects about 360.000 patients in the EU and causes a substantial socioeconomic burden. IPF patients experience a gradual decrease in quality of life due to progressive dyspnoe and coughing, and usually die within 3-5 years upon diagnosis. There is currently no approved treatment available. Our translational research programme includes implementation of a European IPF registry (eurIPFreg), in which data with regard to natural course, familiar background and susceptibility factors of IPF will be collected, and of a European IPF biobank (eurIPFbank) of blood, bronchoalveolar lavage fluid, cells and tissue specimen of IPF. In these samples, we will perform transcriptome, proteome, phosphoproteome and lipidome analysis, cellular studies and genetic analysis to unravel the molecular pathways underlying IPF and to identify and establish new diagnostic and prognostic markers. Candidate gene verification will be performed in cell culture and animal studies, including siRNA and gene transfection technologies and development of genetically altered mice and will result in the development of new animal models of IPF. Identification of new therapeutic targets in these models will be followed by rapid commercial exploitation and early preclinical and early clinical evaluation. Ultimately, we wish to establish a unique, sustainable and internationally unrivalled European infrastructure for investigation and treatment of IPF. Our mission statement is straight-forward and clear: “Fighting for improved survival in Idiopathic Pulmonary Fibrosis”.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinatore

JUSTUS-LIEBIG-UNIVERSITAET GIESSEN

Indirizzo

Ludwigstrasse 23
35390 Giessen

Germania

Tipo di attività

Higher or Secondary Education Establishments

Contributo UE

€ 1 189 546,50

Contatto amministrativo

Sandy Jones (Ms.)

Partecipanti (11)

Classifica in ordine alfabetico

Classifica per Contributo UE

Espandi tutto

UNIVERSITY COLLEGE LONDON

Regno Unito

Contributo UE

€ 322 880

ROYAL BROMPTON AND HAREFIELD NATIONAL HEALTH SERVICE TRUST

Regno Unito

Contributo UE

€ 160 620

UNIVERSITA DEGLI STUDI DI CATANIA

Italia

Contributo UE

€ 232 336

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Francia

Contributo UE

€ 480 218

KLINIKUM DER UNIVERSITAET REGENSBURG

Germania

Contributo UE

€ 59 700

JERINI AG

Germania

Contributo UE

€ 137 398,50

MEDIZINISCHE UNIVERSITAET WIEN

Austria

Contributo UE

€ 68 700

KLINIKUM DER UNIVERSITAET ZU KOELN

Germania

TransMIT Gesellschaft fuer Technologietransfer mbH

Germania

Contributo UE

€ 20 250

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germania

Contributo UE

€ 170 640

RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN

Germania

Contributo UE

€ 156 300

Informazioni relative al progetto

ID dell’accordo di sovvenzione: 202224

Stato

Progetto concluso

  • Data di avvio

    1 Gennaio 2008

  • Data di completamento

    30 Giugno 2011

Finanziato da:

FP7-HEALTH

  • Bilancio complessivo:

    € 3 932 864,20

  • Contributo UE

    € 2 998 589

Coordinato da:

JUSTUS-LIEBIG-UNIVERSITAET GIESSEN

Germania